Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06674577 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Study acronym: ORIGIN EXTEND
StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 476 to 750 Primary and study completion dates: May 31, 2028 to May 21, 2031v5 Show 1 more changeShow less
    • Primary and study completion dates: May 31, 2028 to May 21, 2031
  2. Trial status: Recruiting to Enrolling by Invitation Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  3. Trial status: Not Yet Recruiting to Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  4. Start date: Nov 1, 2024 to Dec 1, 2024 Secondary endpoints: details revised at 1 of 4 entriesv2 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 4 entries
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.
Trial Details
NCT Number NCT06674577
Lead Sponsor Vera Therapeutics, Inc.
Conditions IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
Enrollment 750 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov